Clinical efficacy and safety of a novel controlled-release morphine suppository and subcutaneous morphine in cancer pain: a randomized evaluation.

• DOI: 10.1200/jco.1995.13.6.1520
• Publication Date: 2017-02-23T13:00:10Z
• Authors: E Bruera; R Fainsinger; K Spachynski; N Babul; Z Harsanyi; A C Darke
• Keywords: Suppository

PURPOSE A significant number of cancer patients will require an alternate route morphine administration at some point during their illness. This study compared the clinical efficacy and safety a novel sulfate controlled-release suppository (MS-CRS) subcutaneous (SC) in with pain. METHODS Thirty pain were randomized double-blind crossover to MS-CRS every 12 hours or SC 4 for days each, using 2.5:1 analgesic equivalence ratio. Pain intensity was assessed visual analog scale (VAS) Present Intensity Index McGill Questionnaire. Nausea sedation also VAS. Evaluations made by patient 8 AM, noon, PM, PM rescue consumption recorded. RESULTS Twenty-three completed (13 men 10 women; mean age, 64.0 +/- 2.0 years) treated daily doses 326 69 mg 138 28 mg, respectively. There small but difference overall ordinal pain-intensity scores favor (0.7 0.1 v 0.9 0.1, P = .0459). no differences between VAS 3 13 mm), (23 25 nausea (8 2 9 mm). The did not differ significantly (1.2 0.4 1.2 doses/d). CONCLUSION MS-CRS, administered hours, provides analgesia comparable represents reliable, noninvasive alternative method control unable take oral morphine.